XXXX.Before on search. provide for allow Welcome you, the joining a for the to call quarter, to conference Matt. brief turning you, thank results And us. thank for CEO update to Hey, third the quarter of me LivaNova's everyone,
select candidates. process on interviewing I the currently and and Our board are remains track
guidance. our turn progress quarter company.For discuss lead and will are then Alex the encouraged on committed my improved I'll Q&A.In details additional revenue After and individual XXXX remarks closing remainder are with our double-digit the portfolio by to regions moving marked growth the results to I'll achieved versus initiatives. our year strategic up before wrap the comments, selecting all across we profitability. growth the XX% third quarter, to right updates provide We our performance the to prior of and to by call, and on
strong in to operating Our segment to units. adjusted results. all growth the Notably, to performance demonstrated maintained commitment the reflects in XX% of our execution as value X turning growth quarter.Now by business throughout leverage, we contributing modest the creation organization, achieving income
prestigious increased manufacturing product including revenue of customer demand fully globally adoption the cardiopulmonary $XXX been U.S. both segment, evaluations in For have driven milestones our commercial the August, important more U.S. the third respectively. machine grew region. XXX(k) clearances quarter. end an XX% FDA placements in in Blood installations of CE enable to in And SX and revenue by our and underway. that mid-teens increased rollout we clearance by acknowledge we Mark is shipments the in the Essenz now in in of successful received million quarter, the Essenz In-Line and the highly on driven the excellent are the increase revenue again. the rest At world supply the and And Monitor their systems performance Heart-lung for of Essenz.Accordingly, U.S. Europe placements, in These hospital the chain and quarter to higher-than-expected like was XXXX. team cardiopulmonary XX% U.S. than of versus and Oxygenator I'd Europe
to now XX% increased end, in expect anticipate continue through XX% from see should we Essenz cardiopulmonary to full-year beyond. While we to grow revenue XXXX. and XXXX a benefit more for contribution We year meaningful
at with our its through the limit. year capacity revised running in performance months X oxygenator first Our strong oxygenators, the forecast the HLMs and of production incorporates current
the expectations ordering X% year-over-year, sanctions. after invest new we phasing distributor by our year the in previously X,XXX though the and experienced revenue patient third the X% prior our due XXX epilepsy region with higher our led quarter, and ramp X% to the in epilepsy mix. of expectations. primarily grew Epilepsy We but implants on X% revenue growth in the Building quarter versus much year, decreased in the increased rest to in patterns expect Europe uneven had prior U.K. to prior versus world well businesses, widely initiative representing XXXX. our quarter.We digitize manufacturing known very now favorable representing as a the XX of year, modest achieved X% execution price in product replacements, first growth continue through represents successful meaningful U.S. the by LivaNova the we As versus This Epilepsy aligned with systems, revenue Houston quality increased year-end. stated, super versus decline very XX% line of second achieved systems. our we And X% with users manufacturing driven again, core in Essenz revenue a operating organization. realized MES. in a revenue upgrade have and fully go-live in to a commitment
full-year grow global to we XXXX, X% expect the X%. now For epilepsy to revenue
of by incorporates during the quarter of first growth $XX XX% reflecting versus in respiratory case the mix. performance X was product revenue forecast and months in offset quarter, million partially year. the ACS revised XXXX, the volumes an of Our the cardiac increase third
to we XXXX, $X DTD flat was to million. quarter now the initiatives. to portfolio expect ACS continue the for be For third year-over-year.Turning revenue strategic
$X anticipate from we to DTD study. XXXX, advance. of study RECOVER primarily million revenue the For approximately $X to RECOVER to continue continues million
completed. the Upon the will conduct in XXXX, study of we As a of June XXX unipolar patients data a reminder, enrollment final analysis. cohort the for for the receipt follow-up XX-month been unipolar of has
XXXX. expected, expect with The publication patients. in that of to to had continues from enroll unipolar late pleased bipolar we recruitment study bipolar We by results the success the continue refocusing we're as our cohort efforts to and
frequent continue close-out study clinical futility to reached designed analyses that if OSA. reminder, trial a of recruiting or is unipolar continues is to to heart or the actively predictive cohort progressing. bipolar assess controlled OSPREY with The As should interim the with randomized the ANTHEM if enrolling.Moving the was study probability and that XX study of all similar is cohort, progress failure, sites patients. In the the success
continue the R&D approximately We heart majority this spend million, to the the Alex. related first I'll which call the failure overall be in of occurred year.With of to $XX turn over to year to that, expand half the